MedLife Reports Strong Turnover Growth Despite Financial Loss
MedLife, a private medical services operator, reported a significant increase in its turnover for the first nine months of the year. The company’s revenue reached RON 2.36 billion (EUR 464 million), reflecting a year-over-year growth of 19.4%. This growth was primarily driven by the expansion of all business lines within the group and the acquisitions completed in 2024 and 2025.
The most notable growth was observed in the hospital divisions, which saw an increase of 39.2%, followed by clinics with a 19.2% rise. Laboratories also showed strong performance, growing by 16.1%, while pharmacies recorded an 11.2% increase.
Despite this positive trend, the company reported a financial loss of RON 6.3 million (EUR 1.2 million) during the same period. This loss was attributed to fluctuations in the exchange rate, which had a significant impact on the company’s financial results.
Operating Expenses and Profit Trends
Operating expenses for the nine-month period amounted to RON 2.24 billion (EUR 440.6 million), marking an increase of 20.2% compared to the corresponding period in 2024. This rise in expenses was largely due to the expansion of operations and increased investment in new facilities and technologies.
However, the company managed to maintain a steady operating profit, which grew by 8.6% from RON 112.9 million (EUR 22.2 million) in 2024 to RON 122.6 million (EUR 24.1 million) in 2025. This indicates that the company is effectively managing its costs despite the challenging economic environment.
Impact of Exchange Rate Fluctuations
The financial loss for the period increased significantly, reaching RON 109.9 million (EUR 21.6 million) as of September 30, 2025. This was a result of the rising exchange rate, which moved from RON 4.9 per EUR 1 at the end of December 2024 to RON 5.08 per EUR 1 by the end of September 2025. Additionally, the revaluation of a syndicated loan denominated in euros contributed to the loss.
The net result for the period represented a loss of RON 6.39 million (EUR 1.3 million), compared to a profit of RON 20.8 million (EUR 4.1 million) in the same period of 2024. This shift was mainly caused by exchange rate fluctuations, highlighting the challenges faced by companies operating in a volatile currency environment.
Financial Position and Strategic Investments
Current liabilities (excluding interest-bearing items) decreased by RON 58.8 million (EUR 11.6 million), or 8%, from RON 711.4 million (EUR 140.0 million) in December 2024 to RON 652.6 million (EUR 128.5 million) in September 2025. This reduction suggests improved liquidity and better management of short-term obligations.
Mihai Marcu, President and CEO of the MedLife Group, emphasized the company’s commitment to long-term growth and innovation. “The results from the first nine months confirm that our growth model is solid and sustainable, even in a more moderate economic environment. The investments we make in technology, automation, genetics, and artificial intelligence are not just expenses, but strategic assets that will generate value in the coming years,” he stated.
Expansion and Technological Advancements
To support its growth strategy, MedLife has accelerated its development in personalized medicine. The company launched Longevity100+, the first genetic testing program in the region. It has also been actively developing artificial intelligence-based solutions to enhance the analysis of medical images and data.
In 2025, the group inaugurated the new operating block of the MedLife Craiova Hospital. In the clinics sector, MedLife invested over EUR 3 million (RON 15.3 million) in Pitești through the opening of a new large medical unit. Additionally, the company opened the first fully automated laboratory in Brașov, with an investment of over EUR 2 million (RON 10.2 million).
These developments underscore MedLife’s commitment to expanding its services and leveraging technology to improve healthcare delivery.